218 related articles for article (PubMed ID: 32207987)
1. Identification of Selective Inhibitors of
Sharma VK; Bharatam PV
J Comput Biol; 2021 Jan; 28(1):43-59. PubMed ID: 32207987
[TBL] [Abstract][Full Text] [Related]
2. Identification of selective
Sharma VK; Kathuria D; Bharatam PV
J Biomol Struct Dyn; 2022; 40(19):8687-8695. PubMed ID: 33904374
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoinformatic Study on the Selective Inhibition of the Protozoan Dihydrofolate Reductase Enzymes.
Sharma VK; Abbat S; Bharatam PV
Mol Inform; 2017 Nov; 36(11):. PubMed ID: 28605138
[TBL] [Abstract][Full Text] [Related]
4. In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
Rana RM; Rampogu S; Abid NB; Zeb A; Parate S; Lee G; Yoon S; Kim Y; Kim D; Lee KW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32752079
[TBL] [Abstract][Full Text] [Related]
5. Homology modelling, molecular docking, and molecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A.
Vadloori B; Sharath AK; Prabhu NP; Maurya R
BMC Res Notes; 2018 Apr; 11(1):246. PubMed ID: 29661206
[TBL] [Abstract][Full Text] [Related]
6. In silico screening of inhibitors against human dihydrofolate reductase to identify potential anticancer compounds.
Soofi A; Rezaei-Tavirani M; Safari-Alighiarloo N
J Biomol Struct Dyn; 2023; 41(23):14497-14509. PubMed ID: 36883866
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening, docking, and dynamics of potential new inhibitors of dihydrofolate reductase from Yersinia pestis.
Bastos Lda C; de Souza FR; Guimarães AP; Sirouspour M; Cuya Guizado TR; Forgione P; Ramalho TC; França TC
J Biomol Struct Dyn; 2016 Oct; 34(10):2184-98. PubMed ID: 26494420
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Gilbert IH
Biochim Biophys Acta; 2002 Jul; 1587(2-3):249-57. PubMed ID: 12084467
[TBL] [Abstract][Full Text] [Related]
10. In silico ADMET study, docking, synthesis and antimalarial evaluation of thiazole-1,3,5-triazine derivatives as Pf-DHFR inhibitor.
Sahu S; Ghosh SK; Gahtori P; Pratap Singh U; Bhattacharyya DR; Bhat HR
Pharmacol Rep; 2019 Oct; 71(5):762-767. PubMed ID: 31351317
[TBL] [Abstract][Full Text] [Related]
11. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
[TBL] [Abstract][Full Text] [Related]
12. Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR.
Jayaraman P; Sakharkar KR; Lim C; Siddiqi MI; Dhillon SK; Sakharkar MK
Drug Des Devel Ther; 2013; 7():449-75. PubMed ID: 23818757
[TBL] [Abstract][Full Text] [Related]
13. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.
Pandey RK; Sharma D; Bhatt TK; Sundar S; Prajapati VK
J Biomol Struct Dyn; 2015; 33(12):2541-53. PubMed ID: 26305585
[TBL] [Abstract][Full Text] [Related]
14. Repurposing FDA-approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach.
Verma K; Chaturvedi R; Lahariya AK; Verma AK; Schneider KA; Anvikar AR; Bharti PK
J Cell Biochem; 2024 Mar; 125(3):e30533. PubMed ID: 38345373
[TBL] [Abstract][Full Text] [Related]
15. Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition.
Adane L; Patel DS; Bharatam PV
Chem Biol Drug Des; 2010 Jan; 75(1):115-26. PubMed ID: 19895504
[TBL] [Abstract][Full Text] [Related]
16. Sesquiterpene Lactones with Dual Inhibitory Activity against the
Possart K; Herrmann FC; Jose J; Costi MP; Schmidt TJ
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011381
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Schormann N; Velu SE; Murugesan S; Senkovich O; Walker K; Chenna BC; Shinkre B; Desai A; Chattopadhyay D
Bioorg Med Chem; 2010 Jun; 18(11):4056-66. PubMed ID: 20452776
[TBL] [Abstract][Full Text] [Related]
18. Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein-ligand interaction studies.
Maganti L; Manoharan P; Ghoshal N
J Mol Model; 2010 Sep; 16(9):1539-47. PubMed ID: 20174846
[TBL] [Abstract][Full Text] [Related]
19. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
20. Discovery of New Schiff Bases Tethered Pyrazole Moiety: Design, Synthesis, Biological Evaluation, and Molecular Docking Study as Dual Targeting DHFR/DNA Gyrase Inhibitors with Immunomodulatory Activity.
Hassan AS; Askar AA; Naglah AM; Almehizia AA; Ragab A
Molecules; 2020 Jun; 25(11):. PubMed ID: 32498469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
